Page 1

Exhibit 99.1 PRECIPIO EXPECT MORE . Precipio Announces Q2-2026 Financial Results Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position NEW HAVEN , CT , Globenewswire - ( Aug 14 , 2026 ) - Specialty cancer diagnostics company Precipio , Inc. ( NASDAQ : PRPO ) , announces financial results for the second quarter that ended June 30 , 2026 . Below are some of the key financial performance metrics for the Company . For additional results please see the Company's Form 10 - Q which was filed today . • • • Revenue - $ 7.0M vs. $ 6.7M in Q1-2026 , and up 22 % YoY from $ 5.7M in Q2-2025 . This comprised of $ 6.1M in pathology revenue ( up from $ 6.0M in Q1 ) and $ 0.9M in product revenue ( up from $ 0.66M in Q1 ) . Adjusted EBITDA - $ 0.4M vs. $ ( 0.2 ) M in Q1-2026 . The change was driven by increased revenues of $ 0.3 million and a decrease in stock - based compensation expense of $ 0.2M . Cash flow - Cash Flow generated from operations was $ 0.7M in Q2-2026 ; total increase in cash was $ 0.5 million , resulting in an end of quarter cash balance exceeding $ 3M , vs $ 1.1M in Q2-2025 . " As anticipated , Q2 operating performance reflects a healthy recovery and continued momentum across the business , with customer growth generating quarterly revenue surpassing $ 7M for the first time in Company history . Product revenues increased 21 % from the previous high of $ 750K in Q4-2025 , and cash increased to over $ 3M . ” said Ilan Danieli , CEO of Precipio . " We've achieved this level of cash without a financing event , demonstrating the strength of our operations . We're encouraged by the progress we've made and believe we are well positioned to continue building on this momentum . " Additional information and a more in - depth discussion on the Company's Q2-2026 performance will be provided in the shareholder call on August 17th , 2026 , at 5 PM ET . The call will include remarks by management on the Company's core business , followed by a moderated Q & A session . EBITDA and Adjusted EBITDA Reconciliation and Explanation EBITDA ( Earnings Before Interest , Taxes , Depreciation , and Amortization ) is a non - GAAP financial measure that is widely used to evaluate operational performance and pre - tax profitability of emerging growth companies like ours . Management believes Adjusted EBITDA provides investors with a useful perspective on the Company's financial health , particularly where non - cash amortization has an important impact on profitability . Adjusted EBITDA as we define it modifies EBITDA by excluding the non - cash costs of employee stock options and unusual non- operating income and expense . Below is a reconciliation of Net Income , EBITDA and Adjusted EBITDA for the second quarter of 2026 and 2025 : ( $ in millions , unaudited ) Net income / ( loss ) ( GAAP ) Adjustments to net income / ( loss ) : Interest expense , net Income taxes Depreciation Q2-26 Q2-25 $ ( 0.2 ) $ 0.1 $ 0.0 $ 0.0 $ 0.0 $ 0.0 $ 0.0 $ 0.1 $ 0.2 $ 0.2 EBITDA ( non - GAAP ) $ 0.0 $ 0.4 Further Adjustments to EBITDA Stock - based compensation expense Other significant ( income ) expenses Adjusted EBITDA ( non - GAAP ) CASASA $ 0.8 $ 0.4 $ ( 0.4 ) $ ( 0.9 ) $ 0.4 $ ( 0.1 ) Amortization of intangibles